This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychopharmacology  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Fluvoxamine maleate increases early morning concentrations of melatonin in humans.^1-2 The serotonin reuptake inhibitor was therefore assumed to enhance the melatonin production by providing a precursor surplus of serotonin. Alternatively, fluvoxamine might inhibit the melatonin metabolism. The following case report strongly supports the second hypothesis.

A 51-year-old female patient with a family history of sleeplessness suffered from chronic primary insomnia, which had proved resistant to various therapies. Nocturnal serum profiles of melatonin were studied in the condition without drugs, under separate administration of fluvoxamine and melatonin, and under the combined treatment. For the measurements, the patient remained in darkness all night and did not use any substances interfering with the secretion or metabolism of melatonin. Cortisol (Becton Dickinson, Heidelberg, Germany) and melatonin concentrations (anti–rabbit antibodies; Stockgrand Ltd, Guildford, England, and melatonin tracer labeled with iodine 125; Nen Life Sciences Products, Brussels, Belgium) (sensitivity, 2 pg/mL; maximal interassay coefficient of variation, . . . [Full Text of this Article]